Our Company

biOasis Technologies Inc. (TSX-V:BTI) is a publically traded biopharmaceutical company focused on developing and commercializing proprietary pharmaceutical products and diagnostic technologies for central nervous system ("CNS") diseases and disorders. Of particular interest is the creation of therapeutic options for patient management to address the limitations to biodistribution presented by the properties of the blood-brain barrier ("BBB"). 

Our Business Strategy
BTI's business strategy emphasizes out-licensing its technologies to qualified partners, and strategic acquisitions of products and technologies relevant to the diagnosis and management of CNS diseases and disorders.

For more about our current development programs click here...


TRANSCEND is a protein Vector that shuttles existing therapeutic drugs across the Blood-Brain Barrier. In November 2010 Bioasis sponsored a research agreement with the National Research Council of Canada to evaluate the ability of biOasis' compounds to cross the blood-brain barrier using real time-domain in vivo optical imaging.

Media & Research

April 3, 2014
biOasis Presents Results From It's BT2111 Program at International Cancer Research Conference
biOasis Technologies Inc. (TSXV: BTI; OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, will present results from it’s BT2111 program at the 105th Annual Meeting of the American Academy of Cancer Research (AACR) being held April 5th to 9th, 2014, in San Diego, California.